Baroda BNP Paribas Health and Wellness Fund Regular-Growth
Equity
Sectoral-Pharma
₹-0.3% 1D
NAV on
Overview
Chart
Returns
Asset Allocation
Fund Info
Risk & Return Ratio
Fund Overview
Rating
Not Rated
Minimum Investment
₹1000
NAV (Net Asset Value)
₹N/A
AUM (Fund size)
₹520 Cr
Created on
5 June 2025
Fund Ranking
#
/ 16 in Sectoral-Pharma
Risk Level
Very High
Very High
Loading...
Returns
Trailing Return
Rolling Return
6 Month
12.5%
1 Year
10.4%
3 Year (CAGR)
-
All Time (CAGR)
6.3%
Category Return
6 Month
16.8%
1 Year
18.1%
3 Year (CAGR)
21.8%
All Time (CAGR)
17.2%
Asset Allocation
Equity
96.6%
Debt
1.0%
Other
2.4%
Top 5 Holdings
Top 5 Sectors
Apollo Hospitals Enterprise
5.35%
Astrazeneca Pharma India
4.05%
Aurobindo Pharma
3.04%
Cipla
1.13%
Dr. Reddy's Laboratories
1.11%
Fund Information
Expense Ratio
2.74%
Exit Load
Exit Load for units in excess of 10% of the investment,1% will be charged for redemption within 1 year.
Lock-In Period
No Lock-In
Managed By
Sanjay Chawla
June 2025 - Present
Ankeet Pandya
July 2026 - Present
Rohan Korde
May 2026 - Present
Risk & Return Ratio
Sharpe Ratio
Sharpe Ratio evaluates a fund's return relative to its risk. Higher values signify better risk-adjusted performance.
0.00
Standard Deviation
Standard deviation measures the volatility of a fund's returns. The higher the value, the riskier the investment.
0.00
Alpha
Alpha in mutual funds measures excess return relative to a benchmark, indicating a manager's skill at generating returns beyond market performance.
0.00
Beta
Beta in mutual funds indicates a fund's sensitivity to market changes. A beta over 1 means it's more volatile than the market, while below 1 implies less volatility.